AI assistant
Sending…
Oramed Pharmaceuticals Inc. — Director's Dealing 2017
Feb 16, 2017
6965_dirs_2017-02-16_d6f9288f-397c-4442-bcbf-07ee4bfb382e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2017-02-09
Reporting Person: RAKIN KEVIN (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-02-09 | Stock Option (right to buy) | $6.23 | A | 5697 | Acquired | 2027-02-09 | Common Stock (5697) | Direct |
Footnotes
F1: The Stock Option will vest immediately.
More from Oramed Pharmaceuticals Inc.
Interim / Quarterly Report
2026
May 19
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Capital/Financing Update
2026
Feb 20
Major Shareholding Notification
2026
Feb 9
Director's Dealing
2026
Jan 29
Major Shareholding Notification
2026
Jan 29
Director's Dealing
2026
Jan 29